ZBTB7A and hepatocellular carcinoma: In fact, miR-125a has an antiproliferative activity towards HCC cells, is able to mediate the activity of Sorafenib, a drug representing the standard of care for advanced HCC, is downregulated in HCC biopsies in comparison to adjacent non-tumoral tissues and is able to limit tumor growth, in vitro and in vivo, by downregulating different targets such as matrix metalloproteinase-11 (MMP11), sirtuin-7 (SIRT-7), Zbtb7a, and also the stemness factor Lin28b [23,24,25,26,27,28,29,30,31].